The FDA granted closely held Limaca Medical of Israel breakthrough device designation for its Precision-GI endoscopic ultrasound biopsy product. The Precision-GI device is designed to obtain tumor tissue within or...
The efficacy endpoint of First Wave BioPharma’s (NASDAQ:FWBI) Phase 2 RESERVOIR trial with FW-COV did not demonstrate statistical significance, compared to placebo, in removing the SARS-CoV-2 virus from the digestive...
Annovis Bio (NYSE:ANVS) entered a cooperative research and development agreement with the NIH’s National Institute on Aging to develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived...
Closely held PharmaJet presented new research at the World Vaccine Congress about clinical studies across multiple vaccine and therapeutic development programs that have incorporated its needle-free delivery systems...
Dr. Donald Hillebrand Sigyn Therapeutics (OTC:SIGY) appointed Dr. Donald Hillebrand, M.D., to its scientific advisory board. Dr. Hillebrand is the associate medical director of liver transplantation at Saint...
The FDA rejected Ampio Pharmaceuticals’ (NYSE American:AMPE) proposed modified intent-to-treat (mITT) population as the primary analysis population for evaluating efficacy in the AP-013 trial, and the acceptability of...
Closely held LENZ Therapeutics entered into an exclusive license agreement with Ji Xing Pharmaceuticals (JIXING) to develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment...
Altamira Therapeutics (NASDAQ:CYTO) provided a business update as it repositions around RNA therapeutics and continues to progress towards upcoming key catalysts with its non-RNA legacy programs. “We are...
Closely held Viz.ai raised $100-million to expand its artificial-intelligence platform designed to detect and triage strokes, heart attacks and aneurysms by scanning patient imagery. The Series D funding round led by...
The Australian Human Research Ethics Committee has approved Claritas Pharmaceuticals’ (TSXV:CLAS; OTC:CLAZF) submission for the Phase 1 clinical study of R-107 to be conducted at Scientia Clinical Research in Sydney...